Clinical Trial

A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-28
critical Recruitment opened 2026-07-03
Trial Details
NCT Number NCT07649941
Lead Sponsor Boehringer Ingelheim
Conditions Healthy
Enrollment 16 participants
Start Date 2026-06-22
Primary Completion 2026-08-19 (estimated)
Study Completion 2026-08-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-27